In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Abstract Text:

S Mundle,A Iftikhar,V Shetty,S Alvi,S Dameron,S Gregory,B Marcus,S Khan,A Raza,

The present studies illustrate clinical applications of in situ end labelling (ISEL) of DNA to detect apoptosis in a variety of human malignancies including myelodysplastic syndromes (MDS, n=10), non-Hodgkin's lymphoma (NHL, n=10), head and neck cancer (n = 3), breast cancer (n = 1) and cervical cancer (n = 1). These studies also describe a new in situ double labelling technique to detect apoptosis and proliferation (S-phase cells) simultaneously in the same section of plastic embedded tissue. In vivo intravenous infusions of thymidine analogues (i.e. bromodeoxyuridine (BrdU) and/or iododeoxyuridine (IUdR)) followed by their detection with a specific monoclonal antibody in a plastic embedded biopsy, combined with ISEL in the same section, facilitated simultaneous estimations of apoptosis and proliferation. The most salient finding of these studies was excessive apoptosis in MDS including the cells in S-phase as indicated by uniquely double labelled cells in their bone marrow biopsies. On the other hand, a very low degree of apoptosis was observed in NHL and other solid tumours. Moreover, the solid tumours exhibited definite compartments of apoptosis and proliferation. Further experiments are underway to confirm these findings in a larger study in order to design appropriate therapeutic modalities for these disorders.

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Publishing Authors By Initials

S Mundle,A Iftikhar,V Shetty,S Alvi,S Dameron,S Gregory,B Marcus,S Khan,A Raza,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cell death and differentiation

VOLUME: 1

Page Numbers: 117-22

Journal Abbreviation: Cell Death Differ.

ISSN: 1350-9047

DAY: 5

MONTH: Oct

YEAR: 1994

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9437445

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.

AFFILIATION: Rush Cancer Institute and the Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cell Death Differ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours Related Publications

• 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis.
• A child with acute appendicitis.
• An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
• Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin.
• Benign fibrous histiocytoma of the rib.
• Comment on: Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists: reply.
• Comparison of two methods (precipitation manual and fully automated enzymatic) for the analysis of HDL and LDL cholesterol.
• Computer audiogram.
• Current treatment options: impact of cytogenetics on the course of myelodysplasia.
• Disorders of sex development (DSDs), their presentation and management in different cultures.
• Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
• Facilitating treatment of anxiety disorders in patients with comorbid medical illness.
• Immunomodulatory drugs in myelodysplastic syndromes.
• In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.
• In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
• Interferon alpha 2a in patients of chronic hepatitis C.
• Localized lesions in secondary syphilis.
• Myocardial revascularization.
• Power Doppler sonography of breast cancer: does vascularity correlate with node status or lymphatic vascular invasion?
• Re: Obtaining previous mammograms for comparison.
• Silent myocardial ischemia.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• The assessment of risk factors for postoperative nausea and vomiting.
• The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
• The role of family configuration in early childhood intellectual development in the context of an extended family system in Pakistan.
• Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making.